Abstract
Rifampin-resistant mutants of the obligate intracellular pathogen Chlamydia pneumoniae were isolated and characterized, including strains that contained multiple mutations in the rpoB gene encoding the rifampin binding site. The highest MIC of rifampin against a mutant strain exceeded 100 μg/ml, whereas the highest MIC of rifalazil was 0.125 μg/ml. Derivatives of rifalazil (new chemical entities; NCEs) showed from 2∼4 fold lower MICs, as well as 2∼8 fold lower bactericidal concentrations against both wild type and mutant strains when compared with rifalazil. These results suggest that rifalazil and NCEs are appropriate therapeutic agents for the treatment of C. pneumoniae infections from the point of view of potency and resistance development.
Similar content being viewed by others
Article PDF
References
Fujii K, Saito H, Tomioka H, Mae T, Hosoe K . Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob Agents Chemother 39: 1489–1492 ( 1995)
Dietze R . Teixeira L, Rocha LM, Palaci M, Johnson JL, Wells C, Rose L, Eisenach K, Ellner JJ . Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 45: 1972–1976 ( 2001)
Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI . Development potential of rifalazil. Expert Opin Investig Drugs 12: 255–271 ( 2003).
Roblin PM, Reznik T, Kutlin A, Hammerschlag MR . In vitro activities of rifamycin derivatives ABI-1648 (rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 47: 1135–1136 ( 2003)
Stamm WE, Geisler WM, Suchland RJ . Assessment of antimicrobial resistance in Chlamydia trachomatis strains associated with treatment failure or same strain recurrence, pp. 353–360. In Chlamydial infections: Proceedings of the 10th International Symposium on Human Chlamydial Infections. Basim Yeri: GRAFMAT Basim ve Reklam Sanayi Tic. Ltd. Sti., Antalya, Turkey ( 2002)
Kuo C-C, Grayston JT, Hidaka T, Rose LM . A comparison of the in vitro sensitivity of Chlamydia pneumoniae to macrolides and a new benzoxazinorifamycin, KRM-1648. In Expanding indications for the new macrolides, azalides, and streptogramins. Infectious disease and therapy series, Vol. 21, Ed., Zinner SH, et al., pp. 317–321, Marcel Dekker, New York, N.Y. ( 1997)
Campbell LA, Kuo CC, Suchland RJ, Rothstein DM . Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection. Antimicrob Agents Chemother 52: 1855–1858 ( 2008)
Schachter J, West SK, Mabey D, Dawson CR, Bobo L, Bailey R, Vitale S, Quinn TC, Sheta A, Sallam S, Mkocha H, Mabey D, Faal H . Azithromycin in control of trachoma. Lancet 354: 630–635 ( 1999)
Grayston JT . Chlamydia pneumoniae, strain TWAR pneumonia. Annu Rev Med 43: 317–323 ( 1992)
Beatty WL, Morrison RP, Byrne GI . Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 58: 686–699 ( 1994)
Ouellette SP, Hatch TP, AbdelRahman YM, Rose LA, Belland RJ, Byrne GI . Global transcriptional upregulation in the absence of increased translation in Chlamydia during IFNgamma-mediated host cell tryptophan starvation. Mol Microbiol 62: 1387–1401 ( 2006)
Hosoe K, Mae T, Konishi E, Fujii K, Yamashita K, Yamane T, Hidaka T, Ohashi T . Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob Agents Chemother 40: 2749–2755 ( 1996)
Rothstein DM, Shalish C, Murphy CK, Sternlicht A, Campbell LA . Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin Investig Drugs 15: 603–623 ( 2006)
Stamm WE, Batteiger BE, McCormack WM, Totten PA, Sternlicht A, Kivel NM . For the Rifalazil Study Group. A Randomized, Double-Blind Study Comparing Single-Dose Rifalazil With Single-Dose Azithromycin for the Empirical Treatment of Nongonococcal Urethritis in Men. Sex Transm Dis. Feb 8; [Epub ahead of print] ( 2007)
Rothstein DM, Van Duzer J, Sternlicht A, Gilman SC . Rifalazil and other benzoxazinorifamycins in the treatment of Chlamydia-based persistent infections. Arch Pharm (Weinheim) 340: 517–529 ( 2007)
Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN . Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 40: 2655–2657 ( 1996)
Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP . Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 1853–1857 ( 1998)
Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, Hirakata Y, Maesaki S, Tomono K, Tashiro T, Kohno S . Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 42: 621–628 ( 1998)
Park YK, Kim BJ, Ryu S, Kook YH, Choe YK, Bai GH, Kim SJ . Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 6: 166–170 ( 2002)
Wichelhaus TA, Schafer V, Brade V, Boddinghaus B . Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 43: 2813–2816 ( 1999)
Wichelhaus TA, Schafer V, Brade V, Boddinghaus B . Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. J Antimicrob Chemother 47: 153–156 ( 2001)
Murphy CK, Mullin S, Osburne MS, Van Duzer J, Siedlecki J, Yu X, Kerstein K, Cynamon M, Rothstein DM . In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicro Agents Chemother 50: 827–834 ( 2006)
Mullin S, Rothstein DM, Murphy CK . Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes. Antimicrob Agents Chemother 50: 1908–1911 ( 2006)
Suchland RJ, Bourillon A, Denamur E, Stamm WE, Rothstein DM . Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil. Antimicrob Agents Chemother 49: 1120–1126 ( 2005)
Kutlin A, Kohlhoff S, Roblin P, Hammerschlag MR, Riska P . Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob Agents Chemother. 49: 903–907 ( 2005)
Suchland RJ, Geisler WM, Stamm WE . Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 47: 636–642 ( 2003)
Suchland RJ, Brown K, Rothstein DM, Stamm WE . Rifalazil pretreatment of mammalian cell cultures prevents subsequent Chlamydia infection. Antimicrob Agents Chemother 50: 439–444 ( 2006)
Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA . Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104: 901–912 ( 2001)
Xia M, Suchland RJ, Carswell JA, Van Duzer J, Buxton DK, Brown K, Rothstein DM, Stamm WE . Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis. Antimicrob Agents Chemother 49: 3974–3976 ( 2005)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rothstein, D., Suchland, R., Xia, M. et al. Rifalazil Retains Activity Against Rifampin-resistant Mutants of Chlamydia pneumoniae. J Antibiot 61, 489–495 (2008). https://doi.org/10.1038/ja.2008.65
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ja.2008.65